Bilirubin is the yellow-orange pigment produced when heme, the oxygen-binding component of hemoglobin, is broken down. In adults and term newborns, this pigment is transported in the blood bound loosely to albumin, delivered to the liver, conjugated by the enzyme UDP-glucuronosyltransferase 1A1 into water-soluble glucuronides, and excreted in bile. In preterm infants, every step of that pathway is compromised to some degree. Their red blood cell mass is larger relative to body size and their red cells are shorter-lived, producing more bilirubin per kilogram of body weight. Their livers are immature, with reduced conjugating enzyme activity and limited bile flow. Their albumin levels are lower, leaving less binding capacity to keep unconjugated bilirubin safely dissolved in the circulation rather than diffusing into lipid-rich tissues such as the brain.

The concept of kinetics, the time-dependent movement of a substance through the body’s compartments, is central to understanding why preterm jaundice behaves so unpredictably. The production rate of bilirubin, the volume of distribution across the vascular and tissue compartments, the binding equilibrium with albumin, and the rate of hepatic uptake, conjugation, and excretion together determine the shape of the bilirubin concentration curve over the first days and weeks of life. In term infants, these parameters mature rapidly, and serum bilirubin concentrations typically peak between the third and fifth days before declining. In infants born many weeks early, the peak is delayed, the rise can be steeper, and the decline is slower, extending the period during which the infant remains vulnerable.

The clinical stakes of these kinetic differences are high because unconjugated bilirubin is neurotoxic. When serum concentrations exceed the buffering capacity of circulating albumin, free bilirubin crosses the blood-brain barrier and deposits in the basal ganglia and brainstem nuclei, producing the permanent neurological injury known as kernicterus, or in milder forms, the subtle bilirubin-induced neurologic dysfunction that can affect hearing, motor coordination, and development. Preterm infants are at particularly elevated risk because their blood-brain barrier is more permeable, their albumin binding is weaker, and coexisting conditions common in prematurity, including acidosis, hypoxia, infection, and hemolysis, further displace bilirubin from albumin. Treatment thresholds for phototherapy and exchange transfusion in neonatal care are therefore set conservatively at lower bilirubin concentrations for infants of lower gestational age and lower postnatal age.

Phototherapy remains the mainstay of treatment. By absorbing light in the blue spectrum, bilirubin molecules at the skin’s surface undergo photochemical conversion into structural and configurational isomers that can be excreted in bile and urine without hepatic conjugation. The effectiveness of phototherapy, however, depends on kinetic parameters as well: the dose of light delivered, the surface area exposed, the distance of bilirubin from the skin, and the rate at which photoisomers are cleared. In very preterm infants, delicate skin and limited clearance of photoisomers can complicate therapy, and clinicians must balance the benefits of light exposure against risks such as insensible water loss, temperature instability, and retinal exposure. A kinetic framework helps explain why some infants appear to respond rapidly to phototherapy while others, apparently treated identically, show only sluggish declines in serum bilirubin.

Population pharmacokinetic modeling has increasingly been applied to neonatal bilirubin management, borrowing approaches long established in drug development. By pooling serial bilirubin measurements from cohorts of infants of varying gestational ages and weights, models can estimate typical values and inter-individual variability for parameters such as bilirubin production rate, clearance, and volume of distribution. Such models allow simulation of concentration-time profiles under different scenarios, including varying phototherapy intensities, and can support the design of individualized monitoring schedules. The Journal of Perinatology article on bilirubin kinetics contributes to this growing quantitative literature, situating bilirubin dynamics within the broader physiological context of prematurity, where every parameter is shifting with postnatal maturation.

Several practical implications follow from a kinetic perspective on preterm jaundice. First, gestational age and postnatal age should be treated as continuous modifiers of bilirubin handling rather than binary categories, since hepatic conjugating capacity and albumin production mature along gradual trajectories. Second, serial measurement matters more than any single value, because the rate of rise carries kinetic information about the balance between production and clearance that a static number does not convey. Third, co-morbidities alter kinetics in measurable ways: sepsis reduces albumin binding and hepatic uptake, hemolytic conditions multiply production rates, and enteral feeding patterns influence enterohepatic circulation, in which bilirubin deconjugated in the intestine is reabsorbed rather than excreted. Each of these factors shifts the infant’s position relative to treatment thresholds and explains much of the variability that clinicians observe at the bedside.

Transcutaneous bilirubinometry, which estimates serum concentrations through optical measurements at the skin, has expanded access to screening, but its accuracy in extremely preterm infants remains limited by immature skin structure and by the kinetics of bilirubin distribution between the vascular compartment and peripheral tissues. During and after phototherapy, transcutaneous readings can diverge from serum values because photoisomers and bleached products at the skin surface may not reflect central concentrations. Understanding the timing of redistribution between compartments is therefore essential for interpreting measurements correctly, particularly when deciding whether phototherapy can be safely discontinued. Rebound hyperbilirubinemia after cessation of therapy is itself a kinetic phenomenon, driven by redistribution of bilirubin from deeper tissues back into the circulation and by ongoing production that outstrips still-immature clearance.

The broader significance of studies of bilirubin kinetics in preterm infants lies in their potential to move neonatal jaundice management from a threshold-based discipline toward one informed by individual physiology. As datasets grow and models are refined, clinicians may be able to estimate an individual infant’s production and clearance parameters from a handful of early measurements, predict the trajectory of hyperbilirubinemia before it becomes severe, and tailor the intensity and duration of phototherapy accordingly. Research published in the Journal of Perinatology, including this 2026 contribution available at the canonical link https://www.nature.com/articles/s41372-026-02886-5, reflects a sustained international effort to reduce the twin burdens of overtreatment and missed risk in this vulnerable population. For the estimated fifteen million infants born preterm each year worldwide, sharper kinetic understanding translates directly into safer, more precise care during the fragile first weeks of life.

Subject of Research: Bilirubin kinetics in preterm infants

Article Title: Bilirubin kinetics in preterm infants

Article References: Hegyi, T., Cordero, N., Halari, A., & Petrova, A. (2026). Bilirubin kinetics in preterm infants. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02886-5

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02886-5

Keywords: bilirubin kinetics, preterm infants, neonatal jaundice, hyperbilirubinemia, phototherapy, kernicterus, albumin binding, neonatal intensive care, pharmacokinetics, bilirubin clearance, Bilirubin, kinetics